Volume 49 | Number 6 | December 2014

Abstract List

Robin E. Clark Ph.D., Jeffrey D. Baxter M.D., Bruce A. Barton Ph.D., Gideon Aweh M.S., Elizabeth O'Connell M.S., William H. Fisher Ph.D.


To assess the impact of a 2008 dose‐based prior authorization policy for Massachusetts Medicaid beneficiaries using buprenorphine + naloxone for opioid addiction treatment. Doses higher than 16 mg required progressively more frequent authorizations.

Data Sources

Mediciaid claims for 2007 and 2008 linked with Department of Public Health () service records.

Study Design

We conducted time series for all buprenorphine users and a longitudinal cohort analysis of 2,049 individuals who began buprenorphine treatment in 2007. Outcome measures included use of relapse‐related services, health care expenditures per person, and buprenorphine expenditures.

Data Collection/Extraction Methods

We used ‐9 codes and National Drug Codes to identify individuals with opioid dependence who filled prescriptions for buprenorphine. Medicaid and data were linked with individual identifiers.

Principal Findings

Individuals using doses >24 mg decreased from 16.5 to 4.1 percent. Relapses increased temporarily for some users but returned to previous levels within 3 months. Buprenorphine expenditures decreased but total expenditures did not change significantly.


Prior authorization policies strategically targeted by dose level appear to successfully reduce use of higher than recommended buprenorphine doses. Savings from these policies are modest and may be accompanied by brief increases in relapse rates. Lower doses may decrease diversion of buprenorphine.